Ranolazine: A potential new treatment for chronic stable angina

Heart Disease

Volumn 3, Issue 4, 2001, Pages 263-269

  Anderson, J R ^a   Khou, S ^a   Nawarskas, J J ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antianginal; Chronic stable angina; Partial fatty oxidase inhibitor; Ranolazine

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FATTY ACID; GLUCOSE; NITRIC ACID DERIVATIVE; PLACEBO; RANOLAZINE; VERAPAMIL;

ANGINA PECTORIS; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ENERGY METABOLISM; EXERCISE TOLERANCE; FATTY ACID OXIDATION; GLUCOSE OXIDATION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 0035196061     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200107000-00009     Document Type: Review

References (44)

1. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina)
2. The role of nitrates in coronary heart disease
3. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy
4. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents
5. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris
6. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem
7. Ranolazine (RS-43285): A preliminary study of a new anti-anginal agent with selective effect of ischaemic myocardium
8. MARISA. Monotherapy Assessment of Ranolazine in Stable Angina
9. Ranolazine: Antianginal therapy with a novel mechanism: Placebo controlled comparison versus atenolol
10. Protection of the myocardial cell during ischemia
11. Effects of fatty acid oxidation on efficiency of energy production in rat heart
12. Regulation of fatty acid oxidation in the mammalian heart in health and disease
13. Fuel selection in animals
14. Relationship between carbohydrate and lipid metabolism and the energy balance of the heart muscle
15. Glucose metabolism in the ischemic heart
16. Pharmacological profile of ranolazine, a metabolic modulator active in ischaemia
17. The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog
18. +] and pH in a canine model of transient myocardial ischaemia
19. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion
20. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism
21. Protective effects of the novel antiischaemic agent ranolazine (RS-43285) in perfused rat hearts
22. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart
23. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
24. Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active dehydrogenase
25. Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion
26. 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine
27. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle
28. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart
29. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart
30. Palmitoyl-L-carnitine modifies the function of vascular endothelium
31. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondra
32. Novel metabolic modulator ranolazine selectively improves diastolic function in heart failure
33. Effects of a novel metabolic modulator, ranolazine, on exercise tolerance and left ventricular filling dynamics in patients with angina pectoris
34. Effects of ranolazine on left vetricular regional diastolic function in patients with ischemic heart disease
35. Ranolazine improves left ventricular performance in dogs with chronic heart failure
36. Comparative antianginal efficacy and tolerability of ranolazine in diabetic and nondiabetic patients: Results of the MARISA trial
37. Improved exercise performance on ranolazine in patients with chronic angina and a history of heart failure: The MARISA trial
38. Ranolazine: A new anti-ischemic drug which affects myocardial energetics